Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Melanoma Circulating Tumor Cells: Benefits And Challenges Required For Clinical Application, G. Marsavela, Carlos A. Aya-Bonilla, M. E. Warkiani, Elin S. Gray, Mel R. Ziman
Melanoma Circulating Tumor Cells: Benefits And Challenges Required For Clinical Application, G. Marsavela, Carlos A. Aya-Bonilla, M. E. Warkiani, Elin S. Gray, Mel R. Ziman
Research outputs 2014 to 2021
The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.
A Diagnostic Autoantibody Signature For Primary Cutaneous Melanoma, Pauline Zaenker, Johnny Lo, Robert L. Pearce, Phillip Cantwell, Lester Cowell, Mark Lee, Christopher Quirk, Henry Law, Elin S. Gray, Mel R. Ziman Dr
A Diagnostic Autoantibody Signature For Primary Cutaneous Melanoma, Pauline Zaenker, Johnny Lo, Robert L. Pearce, Phillip Cantwell, Lester Cowell, Mark Lee, Christopher Quirk, Henry Law, Elin S. Gray, Mel R. Ziman Dr
Research outputs 2014 to 2021
Melanoma is an aggressive form of skin cancer that is curable by surgical excision in the majority of cases, if detected at an early stage. To improve early stage melanoma detection, the development of a highly sensitive diagnostic test is of utmost importance. Here we aimed to identify antibodies to a panel of tumour associated antigens that can differentiate primary melanoma patients and healthy individuals. A total of 245 sera from primary melanoma patients and healthy volunteers were screened against a high-throughput microarray platform containing 1627 functional proteins. Following rigorous statistical analysis, we identified a combination of 10 autoantibody biomarkers …
Correlation Between Circulating Tumour Dna And Metabolic Tumour Burden In Metastatic Melanoma Patients, Ashleigh Mcevoy, Lydia Warburton, Zeyad Al-Ogaili, Leisl Celliers, Lesley Calapre, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Mel R. Ziman Dr, Elin S. Gray
Correlation Between Circulating Tumour Dna And Metabolic Tumour Burden In Metastatic Melanoma Patients, Ashleigh Mcevoy, Lydia Warburton, Zeyad Al-Ogaili, Leisl Celliers, Lesley Calapre, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Mel R. Ziman Dr, Elin S. Gray
Research outputs 2014 to 2021
Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB). Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR). Results: CtDNA was detected in 23 …